Abstract：
BACKGROUND: Androgenetic alopecia (AGA) is a common and chronic problem characterized by hair follicle miniaturization.
OBJECTIVE: In this study, heat-treated Limosilactobacillus fermentum LM1020 (HT-LM1020) was investigated in human follicle dermal papilla cell (HFDPC), scalp tissue, and clinical trials for patients with AGA.
METHODS: Cell proliferation and the expression of cyclins and cyclin-dependent kinases (CDKs) were measured in HFDPC. The relative gene expression of 5α-reductase and growth factors were investigated in hair scalp. This double-blind, randomized, placebo-controlled clinical trial was conducted over 24 weeks. Primary efficacy was evaluated by measuring hair density, and secondary efficacy was assessed by experts and self-assessment. Changes in the microbiota of the hair scalps were analyzed using 16S metagenome amplicon sequencing.
RESULTS: HT-LM1020 promoted cell growth (p < 0.001) and cyclin B1 expression, and it reduced 5α-reductase and induced fibroblast growth factor 7 (FGF7), FGF10, and epithelial growth factor7 (EGF7) (p < 0.001). In the clinical trial, the experimental group demonstrated an increase in hair density from 133.70 to 148.87 n/cm2 at Week 24 (p < 0.001), while also expressing satisfaction with their hair density, reduced hair loss, and hairline. At Week 24, the total ratio of lactic acid bacteria operational taxonomic unit (OTU) in the scalp increased from 6.65% to 26.19%. At the same period, placebo-controlled group decreased Staphylococcus caprae OTU from 77.95% to 14.57% while experimental group decreased from 65.80% to 41.02%.
CONCLUSIONS: These present results showed that HT-LM1020 was a co-effector of ingredients for anti-hair loss contributing to cell proliferation and the expression of CDKs.
OBJECTIVE: In this study, heat-treated Limosilactobacillus fermentum LM1020 (HT-LM1020) was investigated in human follicle dermal papilla cell (HFDPC), scalp tissue, and clinical trials for patients with AGA.
METHODS: Cell proliferation and the expression of cyclins and cyclin-dependent kinases (CDKs) were measured in HFDPC. The relative gene expression of 5α-reductase and growth factors were investigated in hair scalp. This double-blind, randomized, placebo-controlled clinical trial was conducted over 24 weeks. Primary efficacy was evaluated by measuring hair density, and secondary efficacy was assessed by experts and self-assessment. Changes in the microbiota of the hair scalps were analyzed using 16S metagenome amplicon sequencing.
RESULTS: HT-LM1020 promoted cell growth (p < 0.001) and cyclin B1 expression, and it reduced 5α-reductase and induced fibroblast growth factor 7 (FGF7), FGF10, and epithelial growth factor7 (EGF7) (p < 0.001). In the clinical trial, the experimental group demonstrated an increase in hair density from 133.70 to 148.87 n/cm2 at Week 24 (p < 0.001), while also expressing satisfaction with their hair density, reduced hair loss, and hairline. At Week 24, the total ratio of lactic acid bacteria operational taxonomic unit (OTU) in the scalp increased from 6.65% to 26.19%. At the same period, placebo-controlled group decreased Staphylococcus caprae OTU from 77.95% to 14.57% while experimental group decreased from 65.80% to 41.02%.
CONCLUSIONS: These present results showed that HT-LM1020 was a co-effector of ingredients for anti-hair loss contributing to cell proliferation and the expression of CDKs.
摘要：
背景：雄激素性脱发（AGA）是一个常见的慢性问题，其特征是毛囊小型化。
目的：在本研究中，在人毛囊毛乳头细胞（HFDPC）中研究了热处理的发酵LimosilactobacillusLM1020（HT-LM1020），头皮组织,和AGA患者的临床试验。
方法:在HFDPC中测量细胞增殖以及细胞周期蛋白和细胞周期蛋白依赖性激酶(CDK)的表达。在头发头皮中研究了5α-还原酶和生长因子的相对基因表达。这个双盲,随机化，安慰剂对照临床试验在24周内进行.通过测量头发密度评估主要疗效，次要疗效由专家和自我评估。使用16S宏基因组扩增子测序分析毛发头皮的微生物群的变化。
结果：HT-LM1020促进细胞生长（p<0.001）和细胞周期蛋白B1表达，它降低了5α-还原酶和诱导成纤维细胞生长因子7（FGF7），FGF10和上皮生长因子7(EGF7)(p<0.001)。在临床试验中,实验组在第24周显示毛发密度从133.70增加到148.87n/cm2（p<0.001），同时也对他们的头发密度表示满意，减少脱发，和发际线。在第24周,头皮中乳酸菌操作分类单位(OTU)的总比率从6.65%增加到26.19%。在同一时期,安慰剂对照组葡萄球菌OTU从77.95%下降到14.57%，而实验组从65.80%下降到41.02%。
结论:这些目前的结果表明,HT-LM1020是有助于细胞增殖和CDK表达的抗脱发成分的共同效应物。
目的：在本研究中，在人毛囊毛乳头细胞（HFDPC）中研究了热处理的发酵LimosilactobacillusLM1020（HT-LM1020），头皮组织,和AGA患者的临床试验。
方法:在HFDPC中测量细胞增殖以及细胞周期蛋白和细胞周期蛋白依赖性激酶(CDK)的表达。在头发头皮中研究了5α-还原酶和生长因子的相对基因表达。这个双盲,随机化，安慰剂对照临床试验在24周内进行.通过测量头发密度评估主要疗效，次要疗效由专家和自我评估。使用16S宏基因组扩增子测序分析毛发头皮的微生物群的变化。
结果：HT-LM1020促进细胞生长（p<0.001）和细胞周期蛋白B1表达，它降低了5α-还原酶和诱导成纤维细胞生长因子7（FGF7），FGF10和上皮生长因子7(EGF7)(p<0.001)。在临床试验中,实验组在第24周显示毛发密度从133.70增加到148.87n/cm2（p<0.001），同时也对他们的头发密度表示满意，减少脱发，和发际线。在第24周,头皮中乳酸菌操作分类单位(OTU)的总比率从6.65%增加到26.19%。在同一时期,安慰剂对照组葡萄球菌OTU从77.95%下降到14.57%，而实验组从65.80%下降到41.02%。
结论:这些目前的结果表明,HT-LM1020是有助于细胞增殖和CDK表达的抗脱发成分的共同效应物。
